ArticleDigestive diseases and sciences2026
Safety of Statins in an Asian Cohort with Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsStatin is often under-prescribed in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) due to fear of hepatotoxicity. Limited studies examine the safety of statin in MASLD prospectively. We evaluated the safety of statins in a cohort with biopsy proven MASLD.
methodsThe study cohort comprised patients with biopsy proven MASLD between 2009 and 2022, with clinical data prospectively collected. We compared the liver profiles of patients with or without statins, at baseline and follow-up. We evaluated risk of statin-related hepatotoxicity in a subgroup of patients with advanced fibrosis or higher baseline transaminase elevation.
resultsThere were 215 patients with biopsy proven MASLD, 115(53.5%) were female. The median age of all patients was 59.9 years. A total of 115(53.5%) patients received statins. Simvastatin and atorvastatin were most used (89.5%). NAFLD activity scores and fibrosis stage were similar between the two cohorts. Baseline ALT was higher in the non-statins' cohort (73 U/L vs 57.5 U/L, p < 0.01). The median duration of statins use was 63 months. At follow-up in comparison to baseline, ALT was significantly lower in both statins (57.5 U/L vs 45 U/L, p < 0.01), and non-statins cohort (73 U/L vs 43 U/L, p < 0.01). There was no significant difference in liver enzyme between the cohorts at follow-up. In subgroup of patients with advanced fibrosis, statins use was not associated with worsening of liver enzymes or liver stiffness.
conclusionsIn this cohort with biopsy proven MASLD, the use of statins was well tolerated and not associated with worsening liver enzymes or fibrosis.
Indexed as
Identifiers
41915352What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.